Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Culper Research Says Is Short Xometry

https://twitter.com/CulperResearch/status/1617894150367752198
byBenzinga Newsdesk
January 24, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Cassava Sciences Announces Interim Safety Review Of Simufilam On-Going Phase 3 Trials In Patients With Alzheimer’s Disease; DSMB Recommended The Phase 3 Trials Of Simufilam Continue As Planned, Without Modification

By Benzinga Newsdesk
September 18, 9:16 AM
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials. The DSMB Recommended the Phase 3 Trials of Simufilam

SAVA